S&CO Inc. decreased its stake in Amgen Inc. (NASDAQ:AMGN) by 5.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,600 shares of the medical research company’s stock after selling 1,000 shares during the period. S&CO Inc.’s holdings in Amgen were worth $3,103,000 as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Amgen by 1.5% in the second quarter. Vanguard Group Inc. now owns 46,679,076 shares of the medical research company’s stock worth $7,102,222,000 after buying an additional 673,247 shares during the last quarter. FMR LLC raised its stake in shares of Amgen by 4.0% in the second quarter. FMR LLC now owns 32,386,936 shares of the medical research company’s stock valued at $4,927,672,000 after buying an additional 1,259,875 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in shares of Amgen by 1.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 20,435,310 shares of the medical research company’s stock valued at $3,109,232,000 after buying an additional 271,591 shares in the last quarter. BlackRock Fund Advisors raised its stake in shares of Amgen by 1.1% in the second quarter. BlackRock Fund Advisors now owns 12,971,828 shares of the medical research company’s stock valued at $1,973,664,000 after buying an additional 138,912 shares in the last quarter. Finally, Nordea Investment Management AB raised its stake in shares of Amgen by 37.1% in the second quarter. Nordea Investment Management AB now owns 5,719,168 shares of the medical research company’s stock valued at $870,171,000 after buying an additional 1,547,099 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN) traded up 0.64% on Tuesday, reaching $146.00. 2,939,067 shares of the company traded hands. Amgen Inc. has a 52-week low of $133.64 and a 52-week high of $176.85. The stock has a 50-day moving average of $151.01 and a 200 day moving average of $160.49. The company has a market capitalization of $108.61 billion, a PE ratio of 14.61 and a beta of 1.15.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, October 27th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.79 by $0.23. Amgen had a net margin of 33.63% and a return on equity of 29.27%. The firm had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.73 billion. During the same quarter in the prior year, the business posted $2.72 EPS. The business’s revenue was up 1.5% compared to the same quarter last year. On average, equities analysts forecast that Amgen Inc. will post $11.56 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 8th. Shareholders of record on Wednesday, November 16th will be given a dividend of $1.00 per share. The ex-dividend date is Monday, November 14th. This represents a $4.00 dividend on an annualized basis and a dividend yield of 2.74%. Amgen’s payout ratio is presently 39.92%.

TRADEMARK VIOLATION WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was illegally copied and republished in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2016/11/29/sco-inc-decreases-stake-in-amgen-inc-amgn.html.

Several brokerages recently issued reports on AMGN. RBC Capital Markets set a $190.00 price objective on Amgen and gave the stock a “buy” rating in a report on Sunday, October 30th. Vetr upgraded Amgen from a “sell” rating to a “hold” rating and set a $171.34 price objective for the company in a report on Wednesday, August 3rd. Leerink Swann reiterated a “hold” rating on shares of Amgen in a report on Saturday, September 17th. Credit Suisse Group AG set a $206.00 price objective on Amgen and gave the stock a “buy” rating in a report on Saturday, September 17th. Finally, Robert W. Baird reissued an “outperform” rating and set a $157.00 target price on shares of Amgen in a research report on Friday, August 26th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the company. Amgen presently has a consensus rating of “Buy” and an average price target of $182.04.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.